Physician profile
Poonam Sood
NPI 1578706859
$27,671.14
in general payments reported to CMS, 2019-2025
35 companies · $4,505 in 2025
The $4,505 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,066 · 2020: $3,312 · 2021: $1,530 · 2022: $2,975 · 2023: $9,651 · 2024: $632 · 2025: $4,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,956 · Food and Beverage: $2,414 · Honoraria: $2,233 · Travel and Lodging: $1,997 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,956.00 |
| Food and Beverage | $2,413.53 |
| Honoraria | $2,233.00 |
| Travel and Lodging | $1,996.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $188.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $16,814.25 | 2019-2023 | Dexcom G7 Gss (161) |
| Recordati_rare_diseases_inc. | $3,856.54 | 2025 | Isturisa |
| Mannkind Corporation | $1,806.98 | 2019-2022 | |
| Corcept Therapeutics | $1,216.18 | 2022-2023 | Korlym |
| Novo Nordisk INC | $962.32 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $429.85 | 2019-2024 | Zepbound, Mounjaro, Humulin |
| Amgen INC. | $332.08 | 2019-2025 | Evenity |
| Abbott Laboratories | $315.59 | 2019-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $310.05 | 2019-2020 | |
| Medtronic, INC. | $199.41 | 2022-2025 | Minimed 780g, Mycarelink |
| Novartis Pharmaceuticals Corporation | $195.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $180.02 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.51 | 2019-2020 | |
| Beta Bionics, INC. | $120.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Companion Medical, INC. | $101.96 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $79.25 | 2019 | |
| Horizon Therapeutics Plc | $71.67 | 2019 | |
| Glaxosmithkline, LLC. | $65.46 | 2019 | |
| Ibsa Pharma INC. | $62.04 | 2019-2023 | Tirosint, Licart |
| Insulet Corporation | $60.63 | 2019-2023 | Omnipod |
| Merck Sharp & Dohme LLC | $56.99 | 2019 | |
| Tandem Diabetes Care, INC. | $44.89 | 2019-2020 | |
| Boston Scientific Corporation | $26.88 | 2020 | |
| Cequr Corporation | $25.40 | 2023 | Cequr Simplicity |
| Becton, Dickinson and Company | $23.45 | 2019 | |
| Abbvie INC. | $20.38 | 2023 | Synthroid |
| Vivus LLC | $16.76 | 2020 | |
| Amag Pharmaceuticals, INC. | $15.50 | 2020 | |
| Alk-Abello, INC | $15.12 | 2019 | |
| Valeritas, INC. | $15.06 | 2019 | |
| Amarin Pharma, INC. | $14.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.02 | 2019 | |
| Vertiflex, INC. | $13.09 | 2019 | |
| Medtronic Minimed, INC. | $11.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.